Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Proapoptotic Peptides.
暂无分享,去创建一个
P. Stayton | D. Hockenbery | O. Press | S. Srinivasan | A. Convertine | Anthony J Convertine | H. Kern | Hanna B. Kern | Selvi Srinivasan
[1] P. Stayton,et al. pH and Salt Effects on Surface Activity and Self-Assembly of Copolymers Containing a Weak Polybase. , 2016, Langmuir : the ACS journal of surfaces and colloids.
[2] H. Frey,et al. Biodegradable pH-Sensitive Poly(ethylene glycol) Nanocarriers for Allergen Encapsulation and Controlled Release. , 2015, Biomacromolecules.
[3] D. Baker,et al. Intracellular delivery system for antibody-Peptide drug conjugates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] F. Speleman,et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.
[5] P. Stayton,et al. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[6] David Baker,et al. A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells , 2014, Cell.
[7] P. Stayton,et al. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. , 2013, ACS nano.
[8] S. Cory,et al. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. , 2013, Blood.
[9] P. Stayton,et al. Neutral polymeric micelles for RNA delivery. , 2013, Bioconjugate chemistry.
[10] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[11] S. Pun,et al. Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate. , 2012, Molecular pharmaceutics.
[12] James D Bryers,et al. Multifunctional triblock copolymers for intracellular messenger RNA delivery. , 2012, Biomaterials.
[13] Jaime Rubio-Martinez,et al. Molecular Determinants of Bim(BH3) Peptide Binding to Pro-Survival Proteins , 2012, J. Chem. Inf. Model..
[14] K. Neoh,et al. Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. , 2012, Biomacromolecules.
[15] Chun-Wei Peng,et al. Cathepsin B cleavable novel prodrug Ac‐Phe‐Lys‐PABC‐ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis , 2012, Cancer.
[16] Evripidis Gavathiotis,et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. , 2012, The Journal of clinical investigation.
[17] P. Stayton,et al. Diblock copolymers with tunable pH transitions for gene delivery. , 2012, Biomaterials.
[18] D. Claxton,et al. Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms , 2012, Expert opinion on investigational drugs.
[19] S. Pun,et al. Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[20] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[21] A. Strasser,et al. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases , 2011, The EMBO journal.
[22] P. Stayton,et al. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] D. Benoit,et al. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. , 2010, Molecular pharmaceutics.
[24] Laurent Ducry,et al. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.
[25] D. Benoit,et al. Development of a novel endosomolytic diblock copolymer for siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[26] G. Chinnadurai,et al. BH3-only proteins in apoptosis and beyond: an overview , 2008, Oncogene.
[27] P. Colman,et al. BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.
[28] J. Lutz,et al. Polymerization of oligo(ethylene glycol) (meth)acrylates: Toward new generations of smart biocompatible materials , 2008 .
[29] C. Tse,et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.
[30] Damon L. Meyer,et al. Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.
[31] Laurent Bélec,et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.
[32] R. Hotchkiss,et al. TAT-Bim Induces Extensive Apoptosis in Cancer Cells , 2007, Annals of Surgical Oncology.
[33] James T. Elder,et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. , 2006, Cancer research.
[34] Bonnie F. Sloane,et al. Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.
[35] María J Vicent,et al. Polymer conjugates: nanosized medicines for treating cancer. , 2006, Trends in biotechnology.
[36] Rebecca A. Roberts. Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. , 2005, Drug news & perspectives.
[37] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[38] Brian J. Smith,et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.
[39] L. Juliano,et al. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. , 2004, Analytical biochemistry.
[40] Alfred Nordheim,et al. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S‐independent manner , 2004, Journal of leukocyte biology.
[41] W. Wiczk,et al. Fluorogenic peptide substrates for carboxydipeptidase activity of cathepsin B. , 2004, Acta biochimica Polonica.
[42] Maurizio Pellecchia,et al. Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL , 2004 .
[43] J. Davies,et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 , 2004, Nature Medicine.
[44] Hongsheng Xie,et al. Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.
[45] T. Kipps,et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). , 2004, Chemistry & biology.
[46] John Calvin Reed,et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.
[47] D. Green,et al. Minimal BH3 Peptides Promote Cell Death by Antagonizing Anti-apoptotic Proteins* , 2003, Journal of Biological Chemistry.
[48] Peter D. Senter,et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .
[49] L. Juliano,et al. Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. , 2002, The Biochemical journal.
[50] P. Trail,et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.
[51] A. Bell,et al. Negative Regulation of Epidermal Growth Factor Signaling by Selective Proteolytic Mechanisms in the Endosome Mediated by Cathepsin B* , 1999, The Journal of Biological Chemistry.
[52] G. Dubowchik,et al. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. , 1998, Bioorganic & medicinal chemistry letters.
[53] P. Clarke,et al. Regulation of apoptosis by BH3 domains in a cell-free system , 1997, Current Biology.
[54] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[55] John Calvin Reed,et al. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] J. Mort,et al. Characterization of recombinant rat cathepsin B and nonglycosylated mutants expressed in yeast. New insights into the pH dependence of cathepsin B-catalyzed hydrolyses. , 1992, The Journal of biological chemistry.
[57] P. Stahl,et al. Proteolytic cleavage of ricin A chain in endosomal vesicles. Evidence for the action of endosomal proteases at both neutral and acidic pH. , 1991, The Journal of biological chemistry.
[58] D. Newell,et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. , 1988, Cancer research.
[59] David L. Vaux,et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.
[60] D. Blakey,et al. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. , 1987, Cancer research.
[61] R. Mccauley,et al. Glutathione , 2003, Reactions Weekly.